SkinnyDipped Dark Chocolate Nut Products Recalled

skinnydipped jan24 lt

Seattle, Washington-based SkinnyDipped has recalled a limited quantity of dark chocolate nut products due to an undeclared peanut allergen, the U.S. Food and Drug Administration said.

The recall involves SkinnyDipped Dark Chocolate Cocoa Almond 3.5oz and SkinnyDipped Dark Chocolate Salted Caramel Cashew 3.5oz.

The Cocoa Almond products come with UPC 8-61297-00030-8, lot codes of B22354, B12355, B22355 and B12354, with best by dates between April 20, 2024 and April 21, 2024.

Dark Chocolate Salted Caramel Cashew comes with UPC 8-51562-00841-2, lot codes B23005 and B13006, and best by dates of May 5, 2024 and May 5, 2024.

The affected products were sold in retail stores nationwide from January 8 to January 20, 2023.

The agency noted that the products contained an undeclared peanut allergen in an ingredient from a raw material supplier.

People who have an allergy to peanuts may get serious or life-threatening allergic reactions if they consume these products. The recalled products do not declare peanuts in the ingredient statement or as a disclosed allergen.

However, the company has not received any reports of allergic reactions related to the recalled products to date.

Consumers who have the recalled product are urged to return the packaging for a replacement or refund.

For More Such Health News, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
Follow RTT